Clinical Trial

Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-27
Trial Details
NCT Number NCT07013591
Lead Sponsor Brigham and Women's Hospital
Collaborators: National Institute on Aging (NIA)
Conditions Coronary Artery Bypass Graft
Enrollment 90 participants
Start Date 2026-06-10
Primary Completion 2028-10-01 (estimated)
Study Completion 2029-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-26